ritanserin
Small moleculeexperimental
Ritanserin, also known by its developmental code name R-55667, is a serotonin antagonist medication described as an anxiolytic, antidepressant, antiparkinsonian agent, and antihypertensive agent. It was chiefly investigated as a drug to treat insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant 5-HT2A and 5-HT2C receptor antagonism. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 1992 (NCT00000187)
Timeline
1990s
- Jan 1, 1992
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 2 (5-HT2) receptorINHIBITOR
Serotonin 2 (5-HT2) receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1- Mol. weight
- 477.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRitanserin ↗
- ChEMBLCHEMBL267777 ↗
Also known as
- r-55667
- r-55667
- ritanserin
- ritanserin
- ritanserin
- ritanserin
- tiserton
- tiserton
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000187 | Phase 2 | Jul 1, 1992 | National Institute on Drug Abuse (NIDA), University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 1992 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 1992 |
2 organizations
Page 1 / 1